Form D · Biotechnology
Fortress Biotech, Inc.
New York, NY · CIK 0001429260
Offering snapshot reported Mar 13, 2018 · SEC filing
- Reported sold
- $6.52M Offering amount: $30M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 28, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 13, 2018 | Initial | $6,517,000 | No comparison | 2 | SEC filing |
| Apr 19, 2017 | Initial | $3,254,000 | No comparison | 2 | SEC filing |
| Jul 5, 2011 | Amendment | $25,784,568 | $23,050,729vs Jun 6, 2011 | 344 | SEC filing |
| Jun 6, 2011 | Initial | $2,733,839 | No comparison | 14 | SEC filing |
| May 9, 2011 | Initial | $0 | No comparison | 1 | SEC filing |
| Feb 8, 2011 | Initial | $0 | No comparison | 2 | SEC filing |
| Jan 19, 2011 | Initial | $14,118,534 | No comparison | 1 | SEC filing |
| Jun 8, 2010 | Initial | $3,989,940 | No comparison | 41 | SEC filing |
| May 7, 2010 | Initial | $7,000,000 | No comparison | 25 | SEC filing |
| Aug 4, 2009 | Initial | $1,240,000 | No comparison | 16 | SEC filing |
| Mar 5, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Debt
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $521K
- Finders' fees
- $0
- Form D file number
- 021-307537
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| National Securities Corporation | 7569 | National Securities Corporation · CRD 7569 |
Source: Form D, filed Mar 13, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| George Avgerinos | Executive |
| David J. Barrett | Director |
| Glenn L. Cooper | Director |
| Gary Gemignani | Executive |
| Jimmie Harvey | Director |
| Jimmie Harvey, Jr. | Director |
| Timothy M. Hillman | Executive |
| Malcolm Hoenlein | Director |
| Timothy M. Hofer | Executive |
| Robyn Hunter | Executive |
| Dov Klein | Director |
| Bertrand Liang | Director |
| J. Jay Lobell | Director |
| Lucy Lu | Executive |
| Elizabeth Moore | Executive |
| Stephen Pilatzke | Executive |
| Dale Ritter | Executive |
| Linda Rogers | Executive |
| Michael W. Rogers | Director |
| Lindsay A. Rosenwald | Director, Executive |
| Eric K. Rowinsky | Director |
| Bobby W. Sandage | Executive |
| Raymond J. Tesi | Director, Executive |
| Michael Weiss | Director, Executive |
| Peggy Wentworth | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2 Gansevoort Street 9 Th Floor
New York, NY, 10014
New York, NY, 10014